Vaxcyte (NASDAQ:PCVX) COO Jim Wassil Sells 2,250 Shares of Stock

Vaxcyte, Inc. (NASDAQ:PCVX) COO Jim Wassil sold 2,250 shares of Vaxcyte stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $53.86, for a total value of $121,185.00. Following the transaction, the chief operating officer owned 157,541 shares in the company, valued at approximately $8,485,158.26. This trade represents a 1.41% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jim Wassil also recently made the following trade(s):

• On Wednesday, July 1st, Jim Wassil sold 2,250 shares of Vaxcyte stock. The stock was sold at an average price of $56.33, for a total value of $126,742.50.
• On Monday, June 1st, Jim Wassil sold 2,250 shares of Vaxcyte stock. The shares were sold at an average price of $49.52, for a total value of $111,420.00.

Vaxcyte Stock Up 2.2%

Shares of Vaxcyte stock opened at $55.92 on Thursday. The business has a fifty day simple moving average of $53.56 and a 200-day simple moving average of $55.10. Vaxcyte, Inc. has a fifty-two week low of $29.08 and a fifty-two week high of $65.00. The firm has a market cap of $8.07 billion, a price-to-earnings ratio of -8.13 and a beta of 1.23.

Vaxcyte (NASDAQ:PCVX) last released its earnings results on Wednesday, August 5th. The company reported ($1.97) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.06) by $0.09. During the same period last year, the business earned ($1.22) EPS. Analysts anticipate that Vaxcyte, Inc. will post -7.91 earnings per share for the current fiscal year.

Analysts Set New Price Targets

PCVX has been the subject of a number of research reports. Wall Street Zen cut shares of Vaxcyte from a “sell” rating to a “strong sell” rating in a report on Tuesday, April 28th. Zacks Research cut Vaxcyte from a “hold” rating to a “strong sell” rating in a report on Tuesday, July 14th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Vaxcyte in a research report on Monday, July 6th. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, Vaxcyte has an average rating of “Hold” and an average price target of $86.00.

Institutional Trading of Vaxcyte

Institutional investors and hedge funds have recently bought and sold shares of the stock. NEXTBio Capital Management LP acquired a new stake in Vaxcyte during the 4th quarter valued at $4,406,000. Norges Bank acquired a new stake in shares of Vaxcyte in the fourth quarter worth $56,703,000. Universal Beteiligungs und Servicegesellschaft mbH boosted its position in shares of Vaxcyte by 105.3% in the fourth quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 70,124 shares of the company’s stock worth $3,236,000 after buying an additional 35,974 shares during the period. Eventide Asset Management LLC grew its holdings in shares of Vaxcyte by 141.8% during the fourth quarter. Eventide Asset Management LLC now owns 917,115 shares of the company’s stock valued at $42,313,000 after buying an additional 537,785 shares in the last quarter. Finally, Candriam S.C.A. purchased a new position in shares of Vaxcyte during the first quarter valued at $18,306,000. Institutional investors and hedge funds own 96.78% of the company’s stock.

Key Vaxcyte News

Here are the key news stories impacting Vaxcyte this week:

• Positive Sentiment: Quarterly loss was narrower than expected: Vaxcyte reported second-quarter EPS of negative $1.97, beating the consensus estimate of negative $2.06. Although the loss widened from negative $1.22 a year earlier, the earnings beat likely helped sentiment. Vaxcyte quarterly earnings release
• Positive Sentiment: Important VAX-31 trial updates are approaching: Topline safety, tolerability and immunogenicity data from the adult Phase 3 OPUS-1 trial are expected in the fourth quarter of 2026. Results from the OPUS-2 and OPUS-3 trials are expected in the first half of 2027, giving investors several potential catalysts. Vaxcyte second-quarter 2026 business update
• Positive Sentiment: Strong liquidity reduces near-term financing risk: Vaxcyte had approximately $2.5 billion in cash, cash equivalents and investments as of June 30, 2026, providing substantial funding for its late-stage vaccine programs and development of VAX-A1.
• Neutral Sentiment: Analyst consensus remains cautious: Brokerages recently assigned Vaxcyte a consensus “Hold” rating, suggesting that valuation, clinical execution and the company’s ongoing losses remain areas of investor concern. Vaxcyte consensus rating report
• Negative Sentiment: Several executives sold shares: The CFO, COO and another insider sold a combined 29,250 shares for approximately $1.6 million. Each transaction was conducted under a pre-arranged Rule 10b5-1 plan, which reduces the significance of the sales but may still weigh modestly on sentiment.

About Vaxcyte

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.